Biosimilars
Biosimilars, pioneered by Sandoz, help make biologics accessible to all. The introduction of biosimilars in the EU, where Sandoz is the only company with three marketed products, has already led to significant savings for patients and payors. With many more such products at various stages of the development pipeline, the number of therapeutic areas catered for by biosimilars will increase steadily over the next decade.What They Are
A biosimilar, or follow-on biologic, is a successor to a biologic medicine that has lost patent protection or exclusivity...
Why They Matter
The introduction of biosimilars in the EU has already led to significant savings for patients and payors. With many more...
Biosimilar Development
Biosimilar development requires substantial time and investment. A typical biosimilar takes 7-8 years to develop, at...
Regulation and Approval
The European Medicines Agency (EMA) led the way internationally in 2004 by introducing a new EU-wide regulatory...
